Por favor, use este identificador para citar o enlazar este ítem: https://repositorio.usj.es/handle/123456789/378

Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorMascaraque, Marta-
dc.contributor.authorDelgado-Wicke, Pablo-
dc.contributor.authorNuevo-Tapioles, Cristina-
dc.contributor.authorGracia-Cazaña, Tamara-
dc.contributor.authorAbarca-Lachén, Edgar-
dc.contributor.authorGonzález, Salvador-
dc.contributor.authorCuezva, José M.-
dc.contributor.authorGilaberte, Yolanda-
dc.contributor.authorJuarranz, Ángeles-
dc.date.accessioned2020-04-28T08:07:20Z-
dc.date.available2020-04-28T08:07:20Z-
dc.date.issued2020-03-13-
dc.identifier.citationMascaraque, M., Delgado-Wicke, P., Nuevo-Tapioles, C., Gracia-Cazaña, T., Abarca-Lachen, E., González, S., . . . Juarranz, Á. (2020). Metformin as an adjuvant to photodynamic therapy in resistant basal cell carcinoma cells. Cancers, 12(3) doi:10.3390/cancers12030668es_ES
dc.identifier.issn2072-6694es_ES
dc.identifier.urihttps://repositorio.usj.es/handle/123456789/378-
dc.descriptionPhotodynamic Therapy (PDT) with methyl-aminolevulinate (MAL-PDT) is beingused for the treatment of Basal Cell Carcinoma (BCC), although resistant cells may appear.Normal differentiatedcells depend primarily on mitochondrial oxidative phosphorylation (OXPHOS)to generate energy, but cancer cells switch this metabolism to aerobic glycolysis (Warburg effect),influencing the response to therapies. We have analyzed the expression of metabolic markers(β-F1-ATPase/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) ratio, pyruvate kinase M2(PKM2), oxygen consume ratio, and lactate extracellular production) in the resistance to PDT ofmouse BCC cell lines (named ASZ and CSZ, heterozygous forptch1). We have also evaluated theability of metformin (Metf), an antidiabetic type II compound that acts through inhibition of theAMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway to sensitizeresistant cells to PDT. The results obtained indicated that resistant cells showed an aerobic glycolysismetabolism. The treatment with Metf induced arrest in the G0/G1 phase and a reduction in the lactateextracellular production in all cell lines. The addition of Metf to MAL-PDT improved the cytotoxiceffect on parental and resistant cells, which was not dependent on the PS protoporphyrin IX (PpIX)production. After Metf+MAL-PDT treatment, activation of pAMPK was detected, suppressing themTOR pathway in most of the cells. Enhanced PDT-response with Metf was also observed in ASZtumors. In conclusion, Metf increased the response to MAL-PDT in murine BCC cells resistant toPDT with aerobic glycolysis.es_ES
dc.format.extent19 p.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPI AGes_ES
dc.relationThis research was funded by Spanish grants from Instituto de Salud Carlos III MINECO and Feder Funds (FIS PI15/00974 and PI18/00708) and Ministerio de Ciencia, Innovación y Universidades (SAF2016-75916-R).es_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCarcinoma de células basaleses_ES
dc.subjectTerapia fotodinámicaes_ES
dc.subjectResistenciaes_ES
dc.subjectMarcadores metabólicoses_ES
dc.subjectMetforminaes_ES
dc.titleMetformin as an adjuvant to photodynamic therapy in resistant basal cell carcinoma cellses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.subject.unescoCélulaes_ES
dc.identifier.doi10.3390/cancers12030668es_ES
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses_ES
Aparece en las colecciones: Artículos de revistas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Metformin as an adjuvant to photodynamic therapy in resistant basal cell carcinoma cells.pdf4,14 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro sencillo del ítem


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons